InvivydIVVD
IVVD
About: Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.
Employees: 95
0
Funds holding %
of 7,139 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
100% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 2 (+1) [Q4]
100% more call options, than puts
Call options by funds: $2K | Put options by funds: $1K
15% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 20
4.32% more ownership
Funds ownership: 59.94% [Q3] → 64.26% (+4.32%) [Q4]
1% more funds holding
Funds holding: 76 [Q3] → 77 (+1) [Q4]
8% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 12
53% less capital invested
Capital invested by funds: $73M [Q3] → $34.1M (-$39M) [Q4]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$9
408%
upside
Avg. target
$9.50
437%
upside
High target
$10
465%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Patrick Trucchio 43% 1-year accuracy 76 / 175 met price target | 465%upside $10 | Buy Reiterated | 4 Feb 2025 |
D. Boral Capital Jason Kolbert 36% 1-year accuracy 85 / 239 met price target | 408%upside $9 | Buy Maintained | 3 Feb 2025 |
Financial journalist opinion
Based on 5 articles about IVVD published over the past 30 days
Neutral
GlobeNewsWire
1 week ago
Invivyd to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025
WALTHAM, Mass., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that Marc Elia, Chairman of the Invivyd Board of Directors, will be presenting at the Oppenheimer 35th Annual Healthcare Life Sciences Conference.
Neutral
GlobeNewsWire
2 weeks ago
Invivyd Announces Partnership with Pro Football Coach Jim Harbaugh to Elevate Awareness and Ongoing Impact of COVID-19: Common, Not A Cold
WALTHAM, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced a strategic partnership with renowned professional football coach Jim Harbaugh to raise awareness about the ongoing short and potential long-term risks of COVID-19 to the broad population and especially people who are immunocompromised, and encourage people to learn more about their potential options. This collaboration will highlight Coach Harbaugh in live and social media initiatives.
Positive
Seeking Alpha
2 weeks ago
I See The Bull Case For Invivyd, But I'm Not Married To It
Invivyd, Inc. focuses on developing antibody-based treatments for infectious diseases, primarily COVID-19, with promising projects like PEMGARDA and VYD2311. Strong Q4 performance with a 48% revenue increase for PEMGARDA and a 55% drop in operating expenses highlights Invivyd's potential for profitability. VYD2311 shows significant promise with high neutralization potency and durability, but faces regulatory and competitive challenges before market approval.
Neutral
GlobeNewsWire
2 weeks ago
Invivyd Announces Preliminary Fourth Quarter 2024 Financial Results, Strong Revenue Growth, and Reiterates Goal of Near-Term Profitability
WALTHAM, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced preliminary fourth quarter (Q4) financial results.
Neutral
GlobeNewsWire
3 weeks ago
Invivyd Provides Another Positive SARS-CoV-2 Variant Data Analysis to Satisfy U.S. FDA's Gating Request for Completing Its Review of EUA Request for PEMGARDA™ (pemivibart) for the Treatment of Mild-to-Moderate COVID-19 in Certain Immunocompromised Patients
WALTHAM, Mass., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced the submission to the U.S. Food and Drug Administration (FDA) of an updated immunobridging analysis of pemivibart as ongoing support of a potential amendment to the Emergency Use Authorization (EUA) for pemivibart, a half-life extended investigational monoclonal antibody (mAb), to include the treatment of mild-to-moderate symptomatic COVID-19 in certain immunocompromised patients for whom alternative COVID-19 treatment options are not accessible or clinically appropriate. PEMGARDA™ (pemivibart) received an EUA from the FDA in March 2024 for pre-exposure prophylaxis (PrEP) of COVID-19 in certain adults and adolescents with moderate-to-severe immune compromise.
Neutral
GlobeNewsWire
1 month ago
Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variant XEC
WALTHAM, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that new in vitro neutralization data show continued neutralizing activity of PEMGARDA™ (pemivibart) and pipeline candidate VYD2311 against dominant SARS-CoV-2 variant XEC. As anticipated based on the structural biology of pemivibart and VYD2311, the data are largely consistent with those previously reported for KP.3.1.1. The Centers for Disease Control (CDC) estimates that XEC and KP.3.1.1 accounted for an aggregate 69% of U.S. circulating variants of SARS-CoV-2 for the two weeks ended December 21, 2024. Invivyd generated these new data as part of its ongoing industrial virology effort, which leverages a consistent, high-quality, independent, third-party pseudoviral system that routinely tests authentic Invivyd-produced pemivibart and is supported by extensive structure-based and proprietary analytics.
Neutral
Seeking Alpha
3 months ago
Invivyd, Inc. (IVVD) Q3 2024 Earnings Call Transcript
Start Time: 08:30 January 1, 0000 9:18 AM ET Invivyd, Inc. (NASDAQ:IVVD ) Q3 2024 Earnings Conference Call November 14, 2024, 08:30 AM ET Company Participants Marc Elia - Chairperson, Board of Directors and Executive Committee Tim Lee - COO Bill Duke - CFO Robert Allen - CSO Mark Wingertzahn - SVP of Clinical Development and Medical Affairs Katie Falzone - VP, Corporate Controller Conference Call Participants Maxwell Skor - Morgan Stanley Michael Yee - Jefferies Jason Kolbert - D. Boral Capital Luis Santos - H.C.
Negative
Zacks Investment Research
3 months ago
Invivyd, Inc. (IVVD) Reports Q3 Loss, Misses Revenue Estimates
Invivyd, Inc. (IVVD) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.36 per share a year ago.
Neutral
GlobeNewsWire
3 months ago
Invivyd Reports Third Quarter 2024 Financial Results and Recent Business Highlights
WALTHAM, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced financial results for the quarter ended September 30, 2024, and recent business highlights.
Neutral
GlobeNewsWire
3 months ago
Invivyd Announces New England Journal of Medicine Publishes Letter to the Editor Highlighting Immunobridging Pathway Leading to PEMGARDA™ (pemivibart) Emergency Use Authorization; Comments on Adjacent Third-Party Letter to the Editor
WALTHAM, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announces that The New England Journal of Medicine (NEJM) has published a peer-reviewed Letter to the Editor describing the PEMGARDA™ (pemivibart) immunobridging emergency use authorization (EUA) pathway, as well as an updated correlate of protection (CoP) curve for prevention of symptomatic COVID-19 via recombinant monoclonal antibodies (mAbs) such as pemivibart.
Charts implemented using Lightweight Charts™